Survival Rate of Lung Cancer Patients after Diagnosis in Suranaree University of Technology Hospital, Nakhon Ratchasima Province between 2019 and 2023
Keywords:
lung cancer, survival rate, hospital-basedAbstract
Background and Objective: Lung cancer is a significant public health issue. However, Suranaree University of Technology Hospital had currently no reported studies on the survival rates of lung cancer patients. This study aims to evaluate the survival rates of lung cancer patients following diagnosis and treatment at this institution.
Methods: This is a retrospective cohort study. Data were collected from the medical records of lung cancer patients diagnosed at the Suranaree University of Technology Hospital between January 1, 2019, and December 31, 2023. Of 416 cases and followed up until 2024. The survival rate was estimated using the Kaplan-Meier method. We reported the median survival time and the 95% confidence interval.
Results: Of 416 lung cancer patients, 291 died during the study which corresponding to a case-fatality rate of 52.4 per 100 person-years (95%CI; 46.7-58.8). The median survival time was 0.99 years (95%CI; 0.8-1.3). The respective overall survival experience rate after diagnosis at 1, 3, and 5 years were 49.9% (95%CI; 44.9-54.6), 26.3% (95%CI; 21.6-31.0), and 20.1% (95%CI; 15.2-25.6).
Conclusion: Lung cancer patients treated at the Suranaree University of Technology Hospital have a higher 5–year survival rate in other studies conducted in Thailand. Future studies should investigate the factors in immunotherapy treatment with other treatment modalities on lung cancer survival outcomes.
References
International Agency for Research on Cancer. Cancer today [online]. 2024 [cited May 30, 2024]. Available from: https://gco.iarc.fr/survival/survcan/
Nakhon Ratchasima Provincial Health Office. The lung cancer incidence rate per population [online]. 2024. [cited Jun 25, 2024]. Available from: https://nma.hdc.moph.go.th/hdc/reports/report /report.php?&cat_id=6a1fdf282fd28180eed7d1cfe0155e11&id=cc87b3c4d8148e441447a387c3e070af
Raksasri N, Kamsa-Ard S, Musika W, Santong C, Phunmanee A. Outcomes of treatment, survival rates, and factors related to survival of stage III lung cancer patients treated at Srinagarind hospital, Faculty of Medicine, Khon Kaen University, Thailand. Asian Pac J Cancer Prev 2023;24(5):1743-9. doi:10.31557/APJCP.2023.24.5.1743.
Musika W, Kamsa-ard S, Jirapornkul C, Santong C, Phunmanee A. Survival rate of lung cancer patients after diagnosis in Srinagarind Hospital. Srinagarind Med J 2021;36(1):105-10.
Autkittanon P. Factors associated with survival of elderly patients with advanced non-small cell lung cancer. Bulletin of the Department of Medical Sciences 2021;63(2):275-86.
The Bureau of Registration Administration (BORA).Central Death Registration Database [online]. 2024 [cite2025 Jan 8]. Available from: https://www.bora.dopa.go.th/
Stata. Data analysis and statistical software [online] 2023. [cited Feb 3, 2025]. Available from: https://www.stata.com/
Phutivut V, Chiawiriyabunya I. Survival rate of the five most common cancers in 2010 at Udonthani Cancer Hospital, Thailand. Journal of the Department of Medical Sciences 2019;44(1):81-6.
Saikleam P, Kamsa-ard S, Srisukhumchair N, Seehawong S. Cancer survival rate of patients with cancers and received treatment in Loei Hospital, Loei province, Thailand. Srinagarind Med J 2021;36(6):671-8.
Chaimay B, Woradet S, Putthanachote N, Sarakarn P, Kaewmafai J. Survival and factors associated with Mortality among patients with lung cancer in northeastern Thailand. Journal of Health Research 2024;38(6):545-53.
He S, Li H, Cao M, Sun D, Yang F, Yan X, et al. Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China. Transl Lung Cancer Res 2022;11(8):1591-605. doi:10.21037/tlcr-22-240.
Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Cantero A, Rodríguez-Abreu D, et al. Analysis of diagnostic delay and its impact on lung cancer survival: results from the Spanish Thoracic Tumor Registry. Arch Bronconeumol 2024;60 (Suppl 2):S38-S45. doi:10.1016/j.arbres.2024.07.006.
Lin HT, Liu FC, Wu CY, Kuo CF, Lan WC, Yu HP. Epidemiology and survival outcomes of lung cancer: a population-based study. Biomed Res Int 2019;2019:8148156. doi:10.1155/2019/8148156.
International Agency for Research on Cancer. Survcan [online]. 2025 [cited Feb 3, 2025]. Available from: https://gco.iarc.fr/survival/survcan/dataviz/bars?multiple_populations=0
Abdelhamid A, Tuminello S, Ivic-Pavlicic T, Flores R, Taioli E. Antibiotic treatment and survival in non-small cell lung cancer patients receiving immunotherapy: a systematic review and meta-analysis. Transl Lung Cancer Res 2023;26;12(12):2427-39. doi:10.21037/tlcr-23-597.
Mori S, Ueki Y, Hasegawa M, Nakamura K, Nakashima K, Hidaka T, et al. Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study. PLoS One 2024;19(2):e0298573. doi:10.1371/journal.pone.0298573.
Jeon DS, Kim HC, Kim SH, Kim TJ, Kim HK, Moon MH, et al. Five-year overall survival and prognostic factors in patients with lung cancer: results from the Korean Association of Lung Cancer Registry (KALC-R) 2015. Cancer Res Treat 2023; 55(1):103-111. doi:10.4143/crt.2022.264.
Onal O, Kocer M, Eroglu HN, Yilmaz SD, Eroglu I, Karadogan D. Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer. Turk J Med Sci 2020;50(8):1838-50. doi:10.3906/sag-1912-205.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Srinagarind Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
